4//SEC Filing
Ogden Christopher 4
Accession 0001610717-24-000034
CIK 0001501989other
Filed
Jan 18, 7:00 PM ET
Accepted
Jan 19, 8:41 PM ET
Size
9.8 KB
Accession
0001610717-24-000034
Insider Transaction Report
Form 4
Ogden Christopher
Chief Financial Officer
Transactions
- Award
Common Stock
2024-01-18+40,000→ 88,657 total - Award
Stock Option (Right to Buy)
2024-01-18+154,000→ 154,000 totalExercise: $1.68Exp: 2034-01-17→ Common Stock (154,000 underlying) - Award
Performance Stock Units (PSUs)
2024-01-18+75,000→ 75,000 total→ Common Stock (75,000 underlying)
Footnotes (4)
- [F1]Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2025, subject to the Reporting Person continuing as a service provider through each such date.
- [F2]Includes 70,466 RSUs.
- [F3]1/48th of the shares subject to the option vest on each monthly anniversary measured from January 18, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
- [F4]Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.
Documents
Issuer
CytomX Therapeutics, Inc.
CIK 0001501989
Entity typeother
Related Parties
1- filerCIK 0001914523
Filing Metadata
- Form type
- 4
- Filed
- Jan 18, 7:00 PM ET
- Accepted
- Jan 19, 8:41 PM ET
- Size
- 9.8 KB